This project will address rare immune mediated inflammatory diseases (IMIDs) involving the
lungs, i.e. interstitial pneumonitis (IP). The main objective of this study is to assess the
effects of rituximab (RTX) as a rescue therapy for progressive IMID-IP patients. The primary
study parameter is pulmonary function.
The secondary objectives are to explore the application of imaging with radiolabeled RTX as
early predictor for efficacy of RTX, to study the effects of RTX treatment on quality of
life, and to further elucidate the pathophysiology of IMID-IP by analyzing biochemical
markers.